Nebulised Drug Development Considerations

Nebuliser delivery of drugs offers a patient-friendly means of transforming a medicine into a breathable aerosol. They offer the advantage, over other types of inhaled device (such as pMDIs or DPIs), in that they do not require such strict patient coordination between inhalation and actuation, and so they are effective for the treatment of paediatric, elderly, ventilated and sedated patients.

Intertek Melbourn have been supporting clients’ product development for nearly 30 years across all classes of inhaled and nasal delivery technologies including nebulised therapeutics. In this bite-sized article our Formulation and Manufacturing Lead, David Ward, shares some considerations for successful development of nebulised drugs.

Complete the form to download the article

If you have an immediate enquiry, please either complete the form or call us on (+44) 01763 261 648 discuss how Intertek can help you with your nebulized drug development project.

 
 

 
 
 

 
 
 
 
 
 
34359814907
86
6951/7521/7529/7577/34359740249/
1348
0